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Abstract
Objective: To investigate the use of dopaminergic and serotonergic drugs in elderly people.
Methods: We analyzed data on age, sex and dispensed drugs for individuals aged $65 years registered in the Swedish
Prescribed Drug Register from July to September 2008 (n=1 347 564; 81% of the total population aged $65 years in
Sweden). Main outcome measures were dopaminergic (enhancing and/or lowering) and serotonergic (enhancing and/or
lowering) drugs and combinations of these.
Results: Dopaminergic and serotonergic drugs were used by 5.6% and 13.2% the participants, respectively. Female gender
was related to use of both dopaminergic and, particularly, serotonergic drugs. Higher age was associated with use of
dopamine lowering drugs and serotonergic drugs, whereas the association with use of dopamine enhancing drugs declined
in the oldest old. The occurrence of combinations of dopaminergic and serotonergic drugs was generally low, with
dopamine lowering + serotonin lowering drug the most common combination (1.6%). Female gender was associated with
all of the combinations of dopaminergic and serotonergic drugs, whereas age showed a mixed pattern.
Conclusion: Approximately one out of ten older patients uses serotonergic drugs and one out of twenty dopaminergic
drugs. The frequent use of dopaminergic and serotonergic drugs in the elderly patients is a potential problem due to the
fact that aging is associated with a down-regulation of both these monoaminergic systems. Future studies are needed for
evaluation of the impact of these drugs on different cognitive and emotional functions in old age.
Citation: Johnell K, Fischer H (2011) Dopaminergic and Serotonergic Drug Use: A Nationwide Register-Based Study of Over 1 300 000 Older People. PLoS
ONE 6(8): e23750. doi:10.1371/journal.pone.0023750
Editor: Stefan Kiechl, Innsbruck Medical University, Austria
Received June 7, 2011; Accepted July 23, 2011; Published August 15, 2011
Copyright:  2011 Johnell, Fischer. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported financially by a grant from the Swedish Research Council (dnr 2007-5870) and from Konung Gustav V:s och Drottning
Victorias Frimurarstiftelse (HF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kristina.johnell@ki.se
Introduction
The use of pharmaceutical drugs in today’s society is unevenly
distributed across different age cohorts. Over 90% of older people
($70 years) use drugs compared to less than 65% in younger age
groups (,50 years) [1]. Many drugs affect one or more of the
monoaminergic transmitter systems that have important roles in
different cognitive and emotional processes. This could, in turn,
result in hampered function in these cognitive and affective
domains, as side effects of the drug [2]. Given that age-related
changes in cognition and emotion are in part a consequence of
age-related changes in the brain, it is of interest to investigate how
frequent the use of drugs is that alter dopaminergic and
serotonergic function in older adults brains.
Two monoaminergic systems that have important roles in
cognitive and affective processing are the dopaminergic and the
serotonergic transmitter systems. Many studies have shown that
dopamine is strongly involved in higher cognitive function [3,4]
and that aging is associated with a loss of striatal and extrastriatal
biomarkers [5,6]. Some studies have even indicated a curvelinear
trajectory with accelerated dopamine losses from young-old to
very old age [7–9] and that these age-related dopamine losses are
related to age-related deficits in several different cognitive abilities
[10]. Experimental data now support this latter claim [11]. Studies
in humans have also shown significant decline in the serotonergic
system in normal aging, important for both emotional function
[12,13] and dyfunction [14,15], that are independent of disease
state [16,17]. Recent research also implicate a role for serotonin in
the NMDA receptor antagonist models of cognitive impairment
[18]. The importance of balance between the dopaminergic and
the serotonergic systems for working memory function gives
further evidence for involvement of the serotonin system also in
cognitive function [19].
Little is known about the extent of use of dopaminergic and
serotonergic drugs in the general elderly population. However, the
prevalence of use of certain types of dopaminergic and
serotonergic drugs has been estimated. For instance, recent studies
have reported prevalences of 12–20% for antidepressant [20–23],
5–12% for antipsychotic [20,21,24] and 2% for L-dopa [21] use in
older people.
The aim of the present study was to investigate dopaminergic
and serotonergic drug use in a very large population of elderly
people in a typical modern industrial society (Sweden). These data
will demonstrate how many elderly persons who are potentially
cognitively and emotionally affected by drugs that either enhance
or decrease function in the dopaminergic or serotonergic system.
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Ethics Statement
This study was approved by the ethical board at the Karolinska
Institutet in Stockholm (dnr 2009/477-31/3) and we only
analyzed de-identified data.
Study population
The Swedish Prescribed Drug Register contains individual-
based data for all prescriptions dispensed to the whole population
of Sweden (about 9 million inhabitants) [25]. We analyzed non-
identifiable data from individuals aged $65 years who were
registered in the Swedish Prescribed Drug Register from July to
September 2008 (n=1 347 564), with information on every
individual’s age, sex and dispensed drugs (amount of prescribed
Table 1. Classification of dopaminergic and serotonergic
drugs.
ATC-class Drug type
Dopaminergic drugs
Dopamine enhancing drugs
N04B Anti-Parkinson dopaminergic drugs
N06AF Monoamine oxidase inhibitors, non-
selective
N06AG Monoamine oxidase A inhibitors
N06AX16 Venlafaxine
N06AX21 Duloxetine
N06B Psychostimulants, agents used for ADHD
and
nootropics
Dopamine lowering drugs
N05A Antipsychotics
N05BE01 Buspirone
A03FA01 Metoclopramide
Serotonergic drugs
Serotonin enhancing drugs
N06A Antidepressants
N02CC Antimigraine selective serotonin (5HT1)
agonists
Serotonin lowering drugs
N05AE Atypical antipsychotics; Indole derivatives
N05AH Atypical antipsychotics; Diazepines,
oxazepines, thiazepines and oxepines
N05AX Atypical antipsychotics; Other
antipsychotics
doi:10.1371/journal.pone.0023750.t001
Table 2. Characteristics of the 1 347 564 older people, 2008.
Mean age, years ± SD 76.2±7.9
Sex, % (n)
Women 57.5 (775 109)
Men 42.5 (572 455)
Mean number of dispensed drugs, no. 6 SD 4.563.3
doi:10.1371/journal.pone.0023750.t002
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Dopaminergic and Serotonergic Drug Use
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23750drug, when the prescription was filled, and prescribed dosage
according to the prescriptions written by the prescribers).
Information from the 3 month period about when the
prescription was filled, the amount of drug and the prescribed
dosage was processed to calculate the duration of drug exposure
[26–28]. The time period of 3 months was chosen based on the fact
that drugs are prescribed for use for at most 90 days in Sweden.
When prescribed dosage was incomplete or missing, we based our
calculations of drug exposure on defined daily doses (DDDs) [29].
For each drug, the mean prescribed daily dose (PDD) [29] for
regular use was calculated. In the few cases where the PDD could
not be calculated, we assumed 0.9 DDDs for regularly used drugs
(based on calculations of the total mean value for regularly used
drugs among the elderly in the study population). For drugs
prescribed as needed, 0.45 DDDs (50% of 0.9) was employed. For
dermatological and eye preparations, 1 DDD was assumed [27,28].
A list of current prescriptions was constructed based on the
calculations of the duration of drug exposures for every individual
on the arbitrarily chosen date 30 September 2008. If a patient was
dispensed the same drug in different doses during the study period,
this was counted as one dispensed drug.
Definitions
Drugs were classified according to the Anatomical Therapeutic
Chemical (ATC) classification system [29], as recommended by
the World Health Organization. The classification of dopaminer-
gic (i.e. enhancing and/or lowering) and serotonergic (i.e.
enhancing and/or lowering) drugs [30,31] is shown in Table 1.
Age was categorized into six groups: 65–69, 70–74, 75–79, 80–
84, 85–89 and $90 years.
Statistical analysis
We analyzed the occurrence of dopaminergic and serotonergic
drug use in relation to age and sex. We also investigated the
occurrence of the following combinations of dopaminergic and
serotonergic drugs: dopamine enhancing + dopamine lowering
drug, serotonin enhancing + serotonin lowering drug, dopamine
enhancing + serotonin enhancing drug and dopamine lowering +
serotonin lowering drug.
Logistic regression analysis was used to analyze whether age and
sex were associated with use of dopaminergic and serotonergic
drugs and combinations of these. The results are expressed as odds
ratios (ORs) with 95% confidence intervals (CIs). PASW Statistics
18 for Windows was used for the analyses.
Results
In the study population, mean age was 76.2 years (range 65–109
years), 58% were women and 4.5 drugs were on average used per
person (Table 2).
Dopaminergic drugs were used by 5.6% of the participants and
they were most commonly used by the oldest old (Table 3). The
most frequently used dopaminergic drugs were antipsychotics
(2.8%) and anti-Parkinson dopaminergic drugs (1.8%). Use of
dopamine enhancing drugs were about as common as use of
dopamine lowering drugs. Use of $2 dopamine enhancing (0.6%)
or $2 dopamine lowering drugs (0.3%) was uncommon.
Serotonergic drugs were used by 13.2% of the elderly. The most
frequently used serotonergic drugs were antidepressants (12.3%)
and atypical antipsychotics (1.2%). Use of serotonergic drugs
increased with age and 23.0% of people aged $90 years used these
drugs. Serotonin enhancing drugs were more commonly used than
serotonin lowering drugs, particularly in women. Use of $2
serotonin enhancing (1.7%) or $2 serotonin lowering drugs (0%)
was also uncommon.
Table 4 shows the results of the logistic regression analysis of
whether age and sex were associated with use of dopaminergic and
serotonergic drugs. Female gender was related to use of both
dopaminergic and, particularly, serotonergic drugs, after adjust-
ment for age. Higher age was associated with use of dopamine
lowering drugs and serotonergic drugs, whereas the association
with use of dopamine enhancing drugs declined in the oldest old.
Table 5 shows combinations of dopaminergic and serotonergic
drugs. The occurrence of these combinations was generally low,
with dopamine lowering + serotonin lowering drug the most
common combination (1.6%). The combinations of dopaminergic
and serotonergic drugs were more common in women than in
men. However, the relationship with age showed a mixed pattern.
The prevalence of combinations of serotonin enhancing +
serotonin lowering drug and dopamine lowering + serotonin
lowering drug increased with age, whereas the combinations
dopamine enhancing + dopamine lowering drug and dopamine
enhancing + serotonin enhancing drug showed no clear relation-
ship with age.
Table 4. Adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) for dispensed dopaminergic and serotonergic drugs
in 1 347 564 older people, 2008.
Dopaminergic
drugs
Dopamine
enhancing drugs
Dopamine
lowering drugs
Serotonergic
drugs
Serotonin
enhancing drugs
Serotonin
lowering drugs
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Sex
Man Ref Ref Ref Ref Ref Ref
Woman 1.22 (1.20–1.24) 1.09 (1.07–1.12) 1.33 (1.31–1.36) 1.75 (1.73–1.77) 1.78 (1.76–1.80) 1.27 (1.23–1.31)
Age (years)
65–69 Ref Ref Ref Ref Ref Ref
70–74 1.10 (1.08–1.13) 1.16 (1.12–1.20) 1.06 (1.03–1.10) 1.03 (1.01–1.05) 1.03 (1.01–1.04) 1.18 (1.12–1.24)
75–79 1.27 (1.24–1.31) 1.35 (1.31–1.40) 1.21 (1.17–1.25) 1.25 (1.23–1.27) 1.24 (1.22–1.26) 1.54 (1.46–1.62)
80–84 1.53 (1.50–1.57) 1.43 (1.38–1.47) 1.61 (1.56–1.67) 1.62 (1.59–1.65) 1.58 (1.56–1.61) 2.36 (2.25–2.47)
85–89 1.85 (1.80–1.90) 1.40 (1.35–1.45) 2.21 (2.14–2.28) 2.13 (2.10–2.17) 2.04 (2.00–2.07) 3.60 (3.44–3.78)
$90 2.14 (2.07–2.20) 1.01 (0.96–1.07) 3.08 (2.97–3.19) 2.49 (2.44–2.54) 2.27 (2.23–2.32) 5.05 (4.80–5.32)
doi:10.1371/journal.pone.0023750.t004
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23750Table 6 shows the results of the logistic regression analysis of
whether age and sex were associated with combinations of
dopaminergic and serotonergic drugs. Female gender was
associated with all of the combinations of dopaminergic and
serotonergic drugs, after adjustment for age. Older age was
associated with use of serotonin enhancing + serotonin lowering
drug and dopamine lowering + serotonin lowering drug, after
adjustment for sex. However, age did not show a clear association
with the combinations of dopamine enhancing + dopamine
lowering drug and dopamine enhancing + serotonin enhancing
drug.
Discussion
Main findings
In our large nationwide study, dopaminergic drugs were used by
6% and serotonergic drugs by 13% of the elderly population ($ 65
years). Use of these drugs was associated with female gender and
higher age. Drugs that affect the dopaminergic and serotonergic
systems are used for a wide range of different medical conditions in
older adults. The frequent use of these drugs calls for awareness of
cognitive and emotional side-effects in elderly people. This needs
to be taken into account when making different clinical evaluations
on elderly persons that are based on cognitive or affective deficits.
One important finding in our study is that the use of
dopaminergic and serotonergic drugs increases with age. Given
what is known about accelerated dopamine losses in the brain
from young-old to very-old age [7–9], these two opposing
trajectories suggest a potential increase of dopaminergic side
effect in the older age cohort. This could also be true for
serotonergic drugs, even though there are still too few studies on
age related decline in the serotonergic system [16,17].
Previous studies on young women and men have demonstrated
a sexual dimorphism in neurotransmission, particularly in the
dopamine system [32,33], related to sex differences in cognitive
function [34]. However, given age-related changes in sex
hormones levels, the implications of our gender- related findings
are difficult to evaluate because of the lack of studies on gender
differences in the dopaminergic and serotonergic systems in old
age.
Use of dopaminergic and serotonergic drugs can also cause
severe somatic side effects in older people. Both dopaminergic and
serotonergic drugs have been associated with an increased risk of
fractures [35,36]. In particular, the combination of dopamine
enhancing and serotonin enhancing drugs has been associated
with increased hip fracture risk [35]. This drug combination was
related to female gender in our study, which may be problematic
as women are at greatest risk of fractures [37]. Further, advanced
age and use of serotonergic drugs have previously been associated
with an increased risk of bleeding [31]. In our study, advanced age
was correlated to use of these drugs.
However, dopaminergic and serotonergic drug therapy may
also be efficacious for treatment of depression, psychotic disorders
and Parkinson’s disease in old age [38–41]. Nonetheless, older
people are often underrepresented in clinical trials [42] and,
therefore, there is a lack of high-level evidence for treatment with
dopaminergic and serotonergic drugs in this population.
Limitations
We analysed data on 1 347 564 elderly people registered in the
Swedish Prescribed Drug Register from July to September 2008,
which corresponded to about 81% of the total population aged
$65 years in Sweden (according to Statistics Sweden’s census data
from 30 September 2008). Hence, about 19% of the of the total
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23750Swedish population aged $65 years did not fill a prescription at a
Swedish pharmacy during the study period. The generalizability of
our results to other similar countries is postulated to be high given
that we have analyzed an unselected population. The Swedish
Prescribed Drug Register does not include information about
diagnoses or over-the-counter drugs. In 2008, some antimigraine
selective serotonin (5HT1) agonists were available over the counter
in Sweden, which may lead to an underestimation of the use of
these drugs in our study. Also, the register does not include drugs
used in hospitals or from drug storerooms, which may lead to an
underestimation of drug use in the institutional setting.
Moreover, our method is built on an assumption that all current
drugs were dispensed during the observed 3 month period, due to
the fact that drugs are prescribed for use during at most 90 days in
Sweden. Therefore, we might have disregarded drugs that were
dispensed before the three month period and used at a slower rate
than intended. At the same time, we might have included drugs
that were dispensed during the three month period but
discontinued prematurely. In addition, our method is based on
interpretations of the dispensed drugs’ dosages written by the
prescribers, as well as assumptions about DDDs when information
about dosage was incomplete or missing [26,27]. Finally, a general
limitation of studies on drug registers is that data may not
adequately reflect actual drug use given that adherence to
treatment can be low [43].
Conclusion
Approximately one out of ten older patients uses serotonergic
drugs and one out of twenty dopaminergic drugs. The frequent use
of dopaminergic and serotonergic drugs in the elderly patients is a
potential problem due to the fact that aging is associated with a
down-regulation of both these monoaminergic systems. Future
studies are needed for evaluation of the impact of these drugs on
different cognitive and emotional functions in old age.
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